Jefferies initiated coverage on Keros Therapeutics
$KROS
Biotechnology: Pharmaceutical Preparations
Health Care
Jefferies initiated coverage of Keros Therapeutics with a rating of Buy
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/5/2024 | Buy | Jefferies | |
| 10/24/2024 | Overweight | Cantor Fitzgerald | |
| 10/16/2024 | Sector Outperform | Scotiabank | |
| 9/23/2024 | $96.00 | Buy | Guggenheim |
| 6/25/2024 | $102.00 | Outperform | Oppenheimer |
| 2/21/2024 | Outperform | William Blair | |
| 12/8/2023 | $60.00 | Overweight | Wells Fargo |
| 7/31/2023 | $86.00 | Outperform | Wedbush |
LEXINGTON, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros") (NASDAQ:KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta ("TGF-ß") family of proteins, today announced that three abstracts will be presented from its hematology program at the 66th American Society of Hematology ("ASH") Annual Meeting and Exposition to be held in person and virtually from December 7 through 10, 2024. Keros will be presenting additional results from its two ongoing Phase 2 clinical trials of elrite
LEXINGTON, Mass., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros" or the "Company") (NASDAQ:KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta ("TGF-ß") family of proteins, today announced the appointment of Yung H. Chyung, M.D., as Keros' Chief Medical Officer, effective as of November 1, 2024. "We are thrilled to welcome Yung to Keros and look forward to leveraging his development and TGF-ß superfamily expertise as we continue to advance our clinical programs," said Chair and Chi
LEXINGTON, Mass., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros" or the "Company") (NASDAQ:KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta ("TGF-ß") family of proteins, today announced that Keros' Chair and Chief Executive Officer Jasbir S. Seehra, Ph.D., will participate in a fireside chat presentation at the 2024 Cantor Global Healthcare Conference that will now begin at 8:00 a.m. Eastern time on Thursday, September 19, 2024. A live audio webcast of the fireside chat present
SC 13G/A - Keros Therapeutics, Inc. (0001664710) (Subject)
SC 13G/A - Keros Therapeutics, Inc. (0001664710) (Subject)
SC 13G/A - Keros Therapeutics, Inc. (0001664710) (Subject)
LEXINGTON, Mass., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros" or the "Company") (NASDAQ:KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta ("TGF-ß") family of proteins, today announced the appointment of Yung H. Chyung, M.D., as Keros' Chief Medical Officer, effective as of November 1, 2024. "We are thrilled to welcome Yung to Keros and look forward to leveraging his development and TGF-ß superfamily expertise as we continue to advance our clinical programs," said Chair and Chi
LEXINGTON, Mass., May 28, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros" or the "Company") (NASDAQ:KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta ("TGF-ß") family of proteins, today announced that it appointed Jean-Jacques Bienaimé to its Board of Directors, effective June 1, 2024. "On behalf of the Board, we are delighted to welcome Jean-Jacques to Keros during this pivotal phase of our growth," said President and Chief Executive Officer Jasbir Seehra, Ph.D. "Jean-Jacques is a deeply
LEXINGTON, Mass., April 19, 2023 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros" or the "Company") (NASDAQ:KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological, pulmonary and cardiovascular disorders with high unmet medical need, today announced that it appointed Alpna Seth, Ph.D., to its Board of Directors, effective May 1, 2023. "Dr. Seth's deep industry experience and expertise in drug development, global operations and product launches will be an invaluable addition to our Board of Directors," said President and Chief Executive Officer Jasbir Seehra, Ph.D. "We a
10-Q - Keros Therapeutics, Inc. (0001664710) (Filer)
8-K - Keros Therapeutics, Inc. (0001664710) (Filer)
8-K - Keros Therapeutics, Inc. (0001664710) (Filer)
LEXINGTON, Mass., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros" or the "Company") (NASDAQ:KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta ("TGF-ß") family of proteins, today reported financial results for the quarter ended June 30, 2024. "Keros continued to build upon the progress of all programs across our pipeline in the second quarter of 2024, as evidenced by our recent positive regulatory and data updates from the elritercept (KER-050) program," said Jasbir S. Seehra, Ph.D
Elritercept continued to demonstrate a durable transfusion independence in lower-risk myelodysplastic syndromes, including in patients with high transfusion burden Durable clinical responses were associated with improvements in patient-reported measures of fatigueData from ongoing Phase 2 clinical trial in myelofibrosis continue to demonstrate that elritercept can not only ameliorate ineffective hematopoiesis and address cytopenias, but also provide broader clinical benefit, as supported by observed reductions in spleen volume and improved total symptom scoresKeros will host a corporate update call and webcast today, June 17, 2024, at 8:00 a.m. ET LEXINGTON, Mass., June 17, 2024 (GLOBE NE
LEXINGTON, Mass., June 04, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros" or "Company") (NASDAQ:KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta ("TGF-ß"), today announced that the Company will host a corporate update conference call and webcast on Monday, June 17, 2024 at 8:00 a.m. Eastern time. "I am pleased to announce that Keros received positive feedback from the U.S. Food and Drug Administration regarding the KER-050 (elritercept) myelodysplastic syndromes ("MDS"
Jefferies initiated coverage of Keros Therapeutics with a rating of Buy
Cantor Fitzgerald initiated coverage of Keros Therapeutics with a rating of Overweight
Scotiabank initiated coverage of Keros Therapeutics with a rating of Sector Outperform
Oppenheimer initiated coverage on Keros Therapeutics Inc (NASDAQ:KROS), a clinical-stage biopharmaceutical company that develops and commercializes novel therapeutics for disorders linked to dysfunctional signaling of the transforming growth factor-beta family of proteins. Oppenheimer writes, “Keros is developing best-in-class therapeutics that regulate TGF-β signaling to treat hematological and cardiopulmonary diseases. We consider its pipeline one of the more attractive in biotech today, given its disease-modifying potential in indications with considerable unmet need.” Keros’ lead product candidate, KER-050 (elritercept), is being developed for low blood cell counts or cytopenias, i
Oppenheimer analyst Andreas Argyrides initiates coverage on Keros Therapeutics (NASDAQ:KROS) with a Outperform rating and announces Price Target of $102.
Truist Securities analyst Srikripa Devarakonda maintains Keros Therapeutics (NASDAQ:KROS) with a Buy and maintains $100 price target.
4 - Keros Therapeutics, Inc. (0001664710) (Issuer)
3 - Keros Therapeutics, Inc. (0001664710) (Issuer)
4 - Keros Therapeutics, Inc. (0001664710) (Issuer)